Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms
Blood Advances（2023）
摘要
•Major clone sizes in posttreatment samples are strongly correlated with clinical response.•Inclusion of posttreatment clone size into the prognostic model allows better prognostication for MDS cases treated with azacitidine.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要